Prospective assessment of the role of five tumour markers in breast cancer

Robertson, J. F. R.; Pearson, Derek; Price, Michael R.; Selby, C.; Pearson, J. Matt; Blamey, R.W.; Howell, Anthony

doi:10.1007/bf01741602

Cited by 34 publications

(19 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of such a signal in early-stage disease is precisely what would be expected of an in vivo amplification signal such as the humoral immune response. This is in contrast to cancer-associated antigens, which are markers of tumor burden and not useful for the early detection or screening of breast (22,23) or colorectal cancers (24,25).…”

Section: Discussionmentioning

confidence: 92%

EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer

Lam

Boyle

Healey

et al. 2011

Cancer Prevention Research

128

100

View full text Add to dashboard Cite

Recent publications have reported the technical and clinical validation of EarlyCDT-Lung, an autoantibody test which detected elevated autoantibodies in 40% of lung cancers at diagnosis. This manuscript reports the results of EarlyCDT-Lung run on four new (postvalidation) data sets. The following four cohorts of patients (n ¼ 574) with newly diagnosed lung cancer were identified: group 1 (n ¼ 122), 100% small cell lung cancer (SCLC); group 2 (n ¼ 249), 97% non-small cell lung cancer (NSCLC); group 3 (n ¼ 122), 100% NSCLC; group 4 (n ¼ 81), 62% NSCLC. Serum samples were obtained after diagnosis, prior to any anticancer treatment. Autoantibody levels were measured against a panel of six tumor-related antigens (p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1, and SOX2) in the EarlyCDT-Lung panel and previously established cutoffs applied. In groups 2, 3, and 4, patients were individually matched by gender, age, and smoking history to a control individual with no history of malignant disease. Assay sensitivity was tested in relation to cancer type and stage, and in the matched normals to demographic variables. The autoantibody panel showed sensitivity/specificity of 57%/n.d (not done) for SCLC in group 1, 34%/87% for NSCLC in group 2, 31% and 84% for NSCLC in group 3, and 35%/89% for NSCLC and 43%/89% for SCLC in group 4. There was no significant difference in positivity of EarlyCDT-Lung and different lung cancer stages. These studies confirm the value of an autoantibody assay, EarlyCDT-Lung, as an aid to detecting lung cancer in patients at high risk of the disease. Cancer Prev Res; 4(7); 1126-34. Ó2011 AACR.

show abstract

Section: Discussionmentioning

confidence: 92%

EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer

Lam

Boyle

Healey

et al. 2011

Cancer Prevention Research

128

100

View full text Add to dashboard Cite

show abstract

“…Serum tumor markers, including CEA, AFP, CA 15-3, CA 19-9, CA 125 and TPA have been established and used for the detection of carcinomas (18)(19)(20). CA 15-3 which is considered as a specific marker of breast cancer has been considered as particularly valuable for detection of bone metastases.…”

Section: Discussionmentioning

confidence: 99%

Serum Tumor Markers for Detection of Bone Metastasis in Breast Cancer Patients

et al. 1994

View full text Add to dashboard Cite

“…Because of their lack of organ and tumour specificity, CEA and CA15-3 do not play any role in screening [12][13][14]. However, they can be used in the early detection of recurrent disease [3,[6][7][8][9][10] and therapeutic monitoring.…”

Section: Discussionmentioning

confidence: 99%

Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)

Gioia¹,

Nagel²,

Untch

et al. 2011

Tumor Biol.

View full text Add to dashboard Cite

The aim of this retrospective analysis is to determine the correlation between tumour marker kinetics (TMK) like carcinoembryonic antigen (CEA) and/or cancer antigen (CA) 15-3 and imaging concerning effectiveness of chemotherapy in metastatic breast cancer (MBC) patients. TMK (CEA, AxSYM, Abbott; CA15-3, Elecsys, Roche) were evaluated in MBC patients (n=77) at the beginning of chemotherapy (pre-treatment value=A), after 20-30 days (first intermediate value=B), after 40-60 days (second intermediate value=C) and at the time the effectiveness of chemotherapy was evaluated with imaging (D). Response to treatment was assessed by standard WHO criteria criteria. For the assessment of biochemical progression and response, four criteria based on TMK were established. The first criterion of progression required that there was an increase ≥ 25% after 40-60 days (C) and the slope per day from B to C exceeds the slope from A to B. The second criterion of progression required that, at the time of staging, the value be ≥ 25% of the pre-treatment value (A), and also, increasing values from C until staging (D) were required. The first criterion of response required that the second intermediate value (C) be decreased by ≥ 25% compared to A (pre-treatment value) and C be lower than B (first intermediate value). The second criterion of response required that D be ≤ 25% of B and D be lower than C. Fifty-four (70%) patients showed a correlation between TMK and imaging results during chemotherapy. In 10 (13%) patients, no correlation was obtained, and in 13 (17%) patients, no biochemical statement was possible because of divergent TMK. In summary, after 1 month, no statement about treatment response was possible by using TMK. The effectiveness or ineffectiveness of treatment could be determined correctly in 40% of patients after 2 months and in 70% of patients after approximately 3 months. The data presented support the hypothesis that TMK are clinically relevant tools to monitor treatment response. Further improvements on their sensitivity can be probably achieved by a prospective study design and by combining with other biomarkers like CA-125 and HER2 shed antigen.

show abstract

Prospective assessment of the role of five tumour markers in breast cancer

Cited by 34 publications

References 39 publications

EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer

EarlyCDT-Lung: An Immunobiomarker Test as an Aid to Early Detection of Lung Cancer

Serum Tumor Markers for Detection of Bone Metastasis in Breast Cancer Patients

Kinetics of CEA and CA15-3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC)

Contact Info

Product

Resources

About